Premium
A double‐blind controlled cross‐over trial of cyproterone acetate in females with hidradenitis suppurativa
Author(s) -
MORTIMER P.S.,
DAWBER R.P.R.,
GALES MARY A.,
MOORE R.A.
Publication year - 1986
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1986.tb05740.x
Subject(s) - cyproterone acetate , hidradenitis suppurativa , cyproterone , medicine , free androgen index , norgestrel , regimen , antiandrogen , urology , endocrinology , randomized controlled trial , androgen , disease , population , hormone , sex hormone binding globulin , environmental health , family planning , research methodology
SUMMARY In order to examine whether anti‐androgen therapy was effective in hidradenitis suppurativa (HS), ethinyloestradiol 50μg/cyproterone acetate 50 mg in a reverse sequential regimen was compared with ethinyloestradiol 50μg/norgestrel 500μg (Eugynon 50) in 24 female patients. Both treatments produced substantial improvement in disease activity. Seven patients cleared and have remained free of disease for 18 months, five patients improved, four remained unchanged, while two deteriorated. Cyproterone acetate was not clinically significantly more effective than E50, and both gave a similar reduction in free androgen index. Anti‐androgen therapy appears to be beneficial in the treatment of hidradenitis suppurativa.